Sangamo Therapeutics (NASDAQ:SGMO) Given Sell (E+) Rating at Weiss Ratings

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “sell (e+)” rating restated by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

SGMO has been the topic of several other research reports. Wall Street Zen raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, September 4th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Sangamo Therapeutics currently has an average rating of “Hold” and a consensus target price of $4.50.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO opened at $0.69 on Wednesday. Sangamo Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $3.18. The stock has a market cap of $208.69 million, a price-to-earnings ratio of -2.39 and a beta of 1.22. The firm’s 50-day simple moving average is $0.56 and its 200 day simple moving average is $0.58.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The firm had revenue of $18.31 million for the quarter, compared to the consensus estimate of $31.68 million. On average, sell-side analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Wasatch Advisors LP raised its holdings in shares of Sangamo Therapeutics by 17.7% in the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock worth $4,376,000 after purchasing an additional 1,215,653 shares during the period. Geode Capital Management LLC raised its holdings in shares of Sangamo Therapeutics by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company’s stock worth $1,263,000 after purchasing an additional 48,829 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in shares of Sangamo Therapeutics by 74.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company’s stock worth $851,000 after purchasing an additional 555,323 shares during the period. GSA Capital Partners LLP grew its stake in Sangamo Therapeutics by 2,962.2% in the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock valued at $634,000 after buying an additional 934,649 shares in the last quarter. Finally, Invesco Ltd. grew its stake in Sangamo Therapeutics by 40.6% in the 2nd quarter. Invesco Ltd. now owns 680,452 shares of the biopharmaceutical company’s stock valued at $368,000 after buying an additional 196,558 shares in the last quarter. Institutional investors own 56.92% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.